Omission of axillary lymph node dissection after neoadjuvant chemotherapy for clinically node‐positive breast cancer: How can we select patients?
Open Access
- 10 June 2020
- journal article
- editorial
- Published by Hindawi Limited in The Breast Journal
- Vol. 26 (9), 1869-1870
- https://doi.org/10.1111/tbj.13930
Abstract
Click on the article title to read more.Keywords
This publication has 5 references indexed in Scilit:
- Combined PET–CT and axillary lymph node marking with radioactive iodine seeds (MARI procedure) for tailored axillary treatment in node-positive breast cancer after neoadjuvant therapyBritish Journal of Surgery, 2017
- Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0–T4, N1–N2) Who Receive Neoadjuvant ChemotherapyAnnals of Surgery, 2016
- Marking Axillary Lymph Nodes With Radioactive Iodine Seeds for Axillary Staging After Neoadjuvant Systemic Treatment in Breast Cancer PatientsAnnals of Surgery, 2015
- Tumor Biology Correlates With Rates of Breast-Conserving Surgery and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast CancerAnnals of Surgery, 2014
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisThe Lancet, 2014